Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective, case control study of safety Of Sugammadex Vs. Neostigmine For Reversal Of Neuromuscular Blockade After Surgery

Next Previous
Trial Profile

Retrospective, case control study of safety Of Sugammadex Vs. Neostigmine For Reversal Of Neuromuscular Blockade After Surgery

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sugammadex (Primary) ; Atropine; Glycopyrrolate; Neostigmine
  • Indications Neuromuscular blockade
  • Focus Adverse reactions

Most Recent Events

  • 12 Jan 2022 Results assessing the association between reversal of neuromuscular blocks with sugammadex or neostigmine and a composite of clinically important adverse events in a large surgical cohort, published in the Anesthesia and Analgesia.
  • 06 Nov 2020 New trial record
  • 05 Oct 2020 Results presented at the ANESTHESIOLOGY 2020 Annual Meeting of the American Society of Anesthesiologists

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top